Global Uterine Fibroid Embolization Agents Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Uterine Fibroid Embolization Agents Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. The embolization agents block the arteries supplying blood to the tumor and force them to shrink.
Uterine Fibroid Embolization Agents report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Uterine Fibroid Embolization Agents market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinical Research Institutes and Hospital are the major drivers for the industry.
The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Uterine Fibroid Embolization Agents market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Astellas Pharma
Nippon Kayaku
Pfizer
Boston Scientific Corporation
Merit Medical Systems
Cook Medical
Segment by Type
Gelatin Sponge
Polyvinyl Alcohol (PVA) Particles
Trisacryl Gelatin Microspheres (TAGM)
Polymethyl Methacrylate (PMMA) Microspheres
Others
Clinical Research Institutes
Hospital
Surgical Centers
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Uterine Fibroid Embolization Agents market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Uterine Fibroid Embolization Agents, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Uterine Fibroid Embolization Agents industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Uterine Fibroid Embolization Agents in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Uterine Fibroid Embolization Agents introduction, etc. Uterine Fibroid Embolization Agents Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Uterine Fibroid Embolization Agents market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Uterine Fibroid Embolization Agents report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Uterine Fibroid Embolization Agents market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinical Research Institutes and Hospital are the major drivers for the industry.
The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Uterine Fibroid Embolization Agents market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Astellas Pharma
Nippon Kayaku
Pfizer
Boston Scientific Corporation
Merit Medical Systems
Cook Medical
Segment by Type
Gelatin Sponge
Polyvinyl Alcohol (PVA) Particles
Trisacryl Gelatin Microspheres (TAGM)
Polymethyl Methacrylate (PMMA) Microspheres
Others
Segment by Application
Clinical Research Institutes
Hospital
Surgical Centers
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Uterine Fibroid Embolization Agents market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Uterine Fibroid Embolization Agents, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Uterine Fibroid Embolization Agents industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Uterine Fibroid Embolization Agents in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Uterine Fibroid Embolization Agents introduction, etc. Uterine Fibroid Embolization Agents Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Uterine Fibroid Embolization Agents market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices